Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies
Repair damaged skin, lighten dark spots, reverse hyperpigmentation and achieve smoother, brighter skin in as
These actions make skin look and feel improved
[PUBMED Abstract] Hauschild A, Grob JJ, Demidov LV, et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Death from a cardiovascular event, nonfatal myocardial infarction (heart attack), or nonfatal stroke occurred during the trial in 6.5% of patients who were treated with semaglutide versus 8.0% of patients who received placebo a 20% reduction in relative risk by semaglutide